Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Toronto-based privately owned Dalton Pharma Services has entered into a manufacturing services agreement with Washington-based Oncovir, a specialty pharma company developing nucleic-acid-based clinical therapies for cancer, infectious, immune and degenerative disorders.
Subscribe to our email newsletter
The Cancer Vaccine Acceleration Fund (CVAF) – a joint initiative between the Cancer Research Institute and the Ludwig Institute for Cancer Research – has completed a new investment agreement with Oncovir to enable the production of Oncovir’s immune activator Hiltonol (Poly-ICLC).
The agreement will now provide the Oncovir-CVAF collaboration with Dalton’s API manufacturing and aseptic fill/finish services under cGMP.
Dalton president and CEO Peter Pekos said that having Oncovir on the company’s strategic relationships list with innovative pharmaceutical clients is an important milestone for Dalton.
Oncovir president and CEO Andres Salazar said the company’s strategy to help develop safe, reliable and cost-effective vaccines for some of the most difficult diseases benefits tremendously from having the facilities and technical expertise of Dalton.